NewsDesk @bactiman63 Pennsylvania-based Inovio announced today that the company has dosed the first Phase 2 trial subject in its quest to develop the first vaccine against the Middle East Respiratory...

A Middle East respiratory syndrome coronavirus (MERS CoV) vaccine candidate was shown to be safe, well-tolerated, and induced a robust immune response in a Phase 1 first-in-human clinical trial. Initial...

A collaborative team from The University of Texas Medical Branch at Galveston, Saudi Arabia and Canada developed a potent and safe vaccine that protects against the deadly Middle East respiratory syndrome,...

GeneOne Life Science, Inc. announces that it has received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of...

In a new study, researchers have modified a rabies virus, so that it has a protein from the MERS virus; this altered virus works as a 2-for-1 vaccine that protects mice against both Middle East Respiratory...

New York Blood Center (NYBC) today announced groundbreaking findings toward the development of vaccines for the prevention of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. The findings...

GeneOne Life Science Inc., which partnered with Inovio Pharmaceuticals, Inc. to develop Inovio’s MERS vaccine (GLS-5300), announced Monday the filing of an Investigational New Drug Application (IND)...